The growing interest in women's health, the menopause and use of hormone replacement therapy (HRT) is increasing the demand on laboratories for hormonal assessment of menopausal status. The majority of requests are from general medical practitioners, many of whom provide well-women or menopause clinics. Increasingly, clinicians require objective evidence of the menopausal transition in order to take decisions on a patient's management.
In the light of these developments, it is appropriate to review the literature relating to the measurement of reproductive hormones around the time of the menopause and examine the role of these measurements in the categorization of menopausal status and in the management of patients prescribed HRT. THE 
MENOPAUSE Definitions
The World Health Organization (WHO) definition I of the term menopause is the time of permanent cessation of menstruation due to loss of ovarian follicular activity. Other terms used to describe the time before and after the menopause are given below:
Menopausal transition: the time between the first break in regular menstrual pattern and the menopause. until 12 months of spontaneous amenorrhoea has been observed.
Physiology

The ovary
The menopause can only be identified with certainty I year or more after the event. This is because irregular patterns of menstruation precede the menopause and many women do not progress steadily from pre-to postmenopause (illustrated diagrammatically in Fig. I ). It is generally accepted from studies of Western populations that the average age at the menopause is [49] [50] [51] years. However, entry into the menopausal transition is reported to occur at a median age of 44 years (range years) with a median duration of 4·5 years.?
The menopause is thought to occur when the ovarian pool of oocytes is exhausted. The full complement of oocytes is established in utero during fetal development and is held in an arrested 17) . Small flags indicate the start of menstrual bleeding. The regular spacing of these flags is interrupted at the start of the menopausal transition/perimenopause represented by the first large flag. The second large flag marks the final menstrual period (the menopause). The time to the right ofthisflag is the postmenopause. In the earlypostmenopause there is still some residualovarian activity which is insufficient to result in ovulation or menses. The menopausal transition spans the time between the two large flags i.e. the end of the regular cycles to the menopause. The perimenopause extends for longer until ovarian senescence.
stage of meiosis. Daily recruitment then occurs of a small number of follicles which undergo limited development followed by atresia (cell death), such that by birth, numbers of follicles have already halved to 500 000. This is a process which is independent of gonadotrophins and continues until the menopause. After puberty, around 20 follicles start to develop each month in response to the intermenstrual rise in follicle-stimulating hormone (FSH) . In most casesonly one (dominant) follicle reaches maturity and ovulates, the rest become atretic. Pregnancy and oral contraceptive use have not been shown to delay the menopause, which suggests that the gonadotrophin-independent recruitment of follicles is probably unaffected by these factors. There is some evidence that cigarette smoking and possibly poor nutritional status are risk factors for an early menopause and that this results primarily from an increase in the rate of oocyte atresia.? Destruction of follicles may also be caused by infections or a physical insult such as irradiation or chemotherapy and result in premature ovarian failure.
There is a decline in fertility and alteration in menstrual pattern prior to the menopause. Eventually insufficient oestradiol is produced by the reduced number of ovarian follicles to induce endometrial proliferation and subsequent menstrual bleeding. Perimenopausal women have 10-fold fewer follicles than women the same age with regular menstruation suggesting that the size of the follicular reserveis the major determinant of the transition from regular to irregular menses as well as the menopause itself." Postmenopausally, oestrone becomes the major circulating oestrogen derived from the conversion of adrenal androstenedione in adipose tissue. The changes in reproductive hormones are considered in detail in a later section.
Clinical features and long-term sequelae of the menopause
The perimenopause usually spans several years and over 800/0 of women will experience some symptoms and signs of oestrogen deficiency. These are most commonly hot flushes, genital atrophy and their corollaries of insomnia and sexual dysfunction. Oestrogen target organs, e.g. breast, uterus and vagina contain oestrogen receptors; at a later stage these organs atrophy in the absence of oestrogen leading to vaginitis, urinary frequency, etc. The oestrogen deficiency leads to loss of collagen in skin and ligaments, decreased vascularity of oestrogen responsive tissue and slower transmission of nerve impulses. Ann CUn Biochem 1994: 31 Hot flushes seem to occur only when exposure to the hormone is followed by withdrawal. Patients with Turner's syndrome who have gonadal dysgenesis do not experience hot flushes despite their hypergonadotrophic, low oestrogen state. The mechanism underlying the hot flush is poorly understood since 24% of women with low oestradiol concentrations do not experience them.! However, the effectiveness of HRT in relieving vasomotor symptoms is accepted. It has been suggested that it is the rate of change of oestradiol levels which may trigger the hot flush. S One theory is that declining oestrogen concentrations cause an intermittent downward shift of the hypothalamic temperature setpointthe body then initiates its usual mechanisms to disperse heat at an inappropriately low body temperature. A striking relationship has been demonstrated between luteinizing hormone (LH) pulses and the onset of the hot flush. Since hypothalamic neurones that contain gonadotrophin releasing hormone (GNRH) are situated close to the preoptic anterior nuclei that regulate body temperature, neurotransmitter signals associated with GNRH release may also modify thermoregulating neurones." An alternative theory is based on evidence that sex steroids influence peripheral vascular control; declining oestrogen levels cause more erratic responses to external stimuli. S Vasomotor symptoms persist for at least 2 years in the majority of women.
Of greater impact on long-term morbidity and mortality are the increased risks of osteoporosis and ischaemic heart disease (IHD) in postmenopausal women. Epidemiological studies demonstrate that women suffer an accelerated loss of bone following the menopause? which can be prevented by treatment with oestrogen.! In later life, women are at higher risk of osteoporotic fractures than men, in part because of their reduced bone density. Women with an early natural or iatrogenic menopause? are at increased risk of IHD; the evidence is less clear cut for normal menopause." One of the factors which may account for this is the adversechange in lipid profile with age, i.e. increasedtotal cholesterol and decreased HDL cholesterol. 10 Oestrogen treatment is associated with a decreased risk of IHDll and a beneficial effect on the lipid profile.12 occurred 3-4 years before the menopause, whereas FSH increased significantly 5-6 years before the menopause. Although Metcalf et al. 17 did not detect such an early rise in FSH with any consistency, these authors did find that high concentrations of FSH in urine occurred more frequently in women over 40 years old compared to younger women. Subtle changes in the pituitaryovarian axis can therefore be detected by carefully controlled sampling prior to the onset of irregular menstruation. The selective rise in FSH demonstrated in the follicular phase of women over the age of 40 years may be related to declining secretion of the ovarian glycoprotein hormone, inhibin/" which preferentially inhibits the production andl or secretion of FSH,23 and circulates at highest levels in the luteal phase of the cycle. 22 The endocrine changes discussed above may provide some explanation for the observation authors have used the alternative cross-sectional approach of studying large numbers of women of different ages. 18, 19 Few cross-sectional studies have attempted to standardize the time of blood sampling in the follicular phase in relation to the mid-cycle peak or taken account of the pulsatile nature of gonadotrophin secretion (particularly LH). The longitudinal work provides more detail of the varied hormone levels which occur at this time.
Regular menstruation
The study of Metcalf"? suggests that as long as menstruation remains regular, women over the age of 40 years continue to ovulate in 981170 of cycles. Such women have similar urinary excretion of pregnanediol and oestrogen to fertile younger women and there is little change in the steroid profiles measured in serum.P Other studies, however, have shown that a proportion of women described as having regular menstruation have high follicular phase FSH concentrations in serum, oestradiol concentrations between those found preand postmenopausally, and LH concentrations indistinguishable from controls. 14,18,21.22 It is likely that the women in these studies had already entered or were nearer entry to the menopausal transition period than Metcalf's cohort. For example, Sherman's small group!" were aged 46-56 years and demonstrated an increased frequency of anovulatory cycles and Chakravarti et al." included some women in their study who had not menstruated in the previous 3 months.
Age-related increases in serum gonadotrophin concentrations in women with regular cycles have been reported recently. Lenton et al. 18 divided a group of 127 women aged 23-49 years who had regular ovulatory cycles into 2-year age bands and measured LH and FSH concentrations in serum by radioimmunoassay (RIA) from the tenth to the fifth day prior to the mid-cycle LH surge. By calculating the mean hormone level over the 6 days, the effects of shorter follicular phases and of pulsatile gonadotrophin secretion would be reduced ( Fig. 2 ). Mean LH concentrations remained around 6 U/L until the oldest age band (48-49 years) when the concentration doubled. By contrast, FSH concentrations rose significantly and progressively from 40-41 years such that by age 46-47 years, mean concentrations had almost doubled compared to the younger women, and there was a further increase in the 48-49 group to 15 U/L. On follow-up of 59 women, the rise in LH and FSH concentrations could be related to the time of menopause; the increase in LH Gow, Turner and Glasier- the first break in regular cyclicity, but among women aged 45-55 years with irregular cycles, 800/0 have follicular phase FSH in excess of 15 U/L!9 compared to only 40-500/0 with raised concentrations among those with regular cycles. The measurement of FSH in serum appears to be more sensitive than measurement in an early morning urine;'?
The frequency of high FSH excretion increases with time, occurring on 78% of occasions one year after the onset of irregular menses." However, Metcalf"? reported that this rise in FSH was not invariable as ovulatory cycles occurred at all stages during the menopausal transition when FSH excretion rates returned to normal. Postmenopausal FSH levels do not preclude the possibility of ovulatory cycles. 14, 17, 25 Others have documented the suppression to normal of clearly elevated FSH concentrations in serum (> 30 U/L) following prolonged elevated urinary oestrogen excretion.P The high oestrogen concentrations were explained by evidence of decreased sensitivity of the hypothalamic-pituitary axis to positive feedback of oestrogen. This would result in the absence of a normal midcycle LH peak, anovulation and the continued secretion of oestrogen, possibly from multiple follicles. of a decrease in cycle length around age 40-45 years. 14, 16, 18 The length of the follicular phase decreases by 5-9 days. 14, 18, 24 The higher FSH concentrations may be responsible for the initiation of follicular maturation at more frequent intervals leading to a decrease in cycle length but with maintenance of steroidogenesis." A high FSH level is also associated with decreased fertility, Evidence from pregnancy rates in in vitro fertilization programmes suggests that day 3 FSH levels are a good predictor of outcome: performance declines as FSH rises > 15 U/L and falls off precipitously with elevations >25 U/L, 26, 27 In summary, the most sensitive marker of declining ovarianfunction in women with regular cycles is an elevated follicular phase serum FSH concentration.
FSH
Despite the variability of menstrual pattern during the menopausal transition, a characteristic feature is the appearance of high concentrations of FSH ( Fig. 3 ).14,15,19-21, 25 Metcalf"? found a high urinary FSH in one-third of women at the start of the menopausal transition. There are no equivalent data for serum FSH measured immediately after
Irregular menstruation (menopausal transition)
Most women experience a phase of menstrual irregularity prior to the menopause in which there is a significant reduction in the frequency of ovulatory cycles. In studying urinary pregnanediol measurements in 31 women through the menopausal transition, Metcalf"? found that only 540/0 of cycles were ovulatory. There was also an increased frequency of long cycles (40% lasted more than 40 days) and 80% of these long cycles were anovulatory. This implies a major reduction in fertility-however, pregnancy may still be possible because four women in this study ovulated in their last cycles prior to the menopause. Kaufert 28 has provided evidence from interviews over 3 years with perimenopausal women that there is no steady progress from the pre-to the postmenopause; women might oscillate between stages, become stuck in the perirnenopausal phase or appear to revert to premenopausal patterns. Similarly, hormone levels in urine fluctuate erratically. The only conclusion which Metcalf could make with confidence concerning pituitaryovarian function in individual perimenopausal women was that it was 'unsafe to generalize' and that postmenopausal biochemical parameters were no guarantee of the postmenopausal state.15 LH There is some disagreement in the literature about changes in LH secretion during the menopausal transition. Studies in serum suggest the increase is less consistent than for FSH 14,25 and may occur some years after the rise in FSH and closer to the menopause (Fig. 3 ).18,25 However, Metcalf et al. ,IS using once weekly urine samples found that a persistent (2-8 week) rise in urinary LH excretion with normal concentrations of FSH was a more common event than a rise in FSH without a corresponding rise in LH. Approximately 50070 of the episodes with high LH excretion alone were associated with low oestradiol and could not be explained as a prolongation of the normal mid-cycle surge of LH. FSH has a longer plasma half-life than LH29 but it is not clear whether the high urine LH results can be accounted for by increased renal clearance of LH compared to FSH. Others'? have reported that LH concentrations in urine and serum are more frequently raised than FSH in women with irregular cycles but the influence of possibly sampling near mid-cycle cannot be discounted. The conclusion was still that measurement of FSH in serum discriminated more clearly between women with regular and irregular menses.
Oestradiol and progesterone
Late in the menopausal transition, ovulatory cycles become less frequent, fewer follicles are lutenized, the production of progesterone is limited to a minority of cycles, (Fig. 3 )14,15,11,25 and may be secreted in subnormal amounts.'! There is less consensus as to changes in oestradiol, probably due to the major fluctuations at this time superimposed on the normal cyclical pattern of oestradiol production. Some studies suggest a significant decline in serum oestradiol concentrations even relatively early in the menopausal transition 14,21 whereas others report normal follicular phase concentrations. 19,25 Metcalf et al. 17 observed episodes of normal, low and high oestrogen output in individuals followed throughout the menopausal transition and these were accompanied by either pre-or postmenopausal gonadotrophin excretion rates (there is a good correlation between urine total oestrogen excretion and serum oestradiol concentrations at the perimenopause"), Oscillations between hypo and hyper oestrogenism are a feature of the transition and might explain the occurrence of dysfunctional uterine bleeding."
The longitudinal study of Metcalf et al. 15 enabled the dynamic relationship between oestrogen
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and gonadotrophin secretion to be examined. She observed that gonadotrophin concentrations rose whenever there was a persistently low output of oestrogens. The suppression of LH and FSH in response to rising oestrogen output was sluggish compared to the responsiveness seen in normal ovulatory cycles. The consequent transient occurrence of high oestrogen output with postmenopausal concentrations of FSH appears unique to the perimenopause. The mechanism responsible may involve reduced negative feedback by inhibin 22,25 and/or decreased hypothalamic pituitary sensitivity to the feedback effects of oestrogen.P In summary, a wide variety of hormonal patterns ofLH, FSH and oestradiol can occur in serum during the perimenopause with raisedFSH being arguably the most consistent feature.
Poslmenopause
LH, FSH and oestradiol
Cross-sectional studies of hormone levels in plasma taken from women in whom the diagnosis of menopause was established retrospectively, suggest that 20-40070 of women have oestrogen concentrations indicative of follicular function during the first 6-12 months after the permanent cessation of menses. 13,30 By 12-24 months, the oestrogen concentrations have fallen into the postmenopausal range in almost all subjects. Primordial follicles can still be found in some postmenopausal ovaries but are rarely seen 3 years postmenopause."
Metcalf et al. 16 highlighted the fact that the fluctuating hormone concentrations of the menopausal transition did not stop at the menopause, elevated oestrogen excretion occurred in five of eight women during the first 6 postmenopausal months. Urinary LH and FSH excretion was no different in the first 5 weeks after the menopause compared to before it, although by [15] [16] [17] [18] [19] [20] weeks, gonadotrophin concentrations were slightly higher. The menopause was associated with only one clear hormonal change-invariably low pregnanediol excretion in the 6 months that followed implying cessation of ovulation. Since this represents a continuation of the pattern seen in many anovulatory perimenopausal women, it is clear that the early postmenopausal period cannot be distinguished clinically or biochemically from the irregular pattern which is common before the menopause.
Chakravarti et al." studied plasma hormone concentrations in a cross-section of 60 women who had been postmenopausal for 1-30 years. FSH and LH reached their maximum 2-3 years after the menopause and the increase compared to normal follicular concentrations was greater for FSH (Table 1) . Subsequently, there was a gradual decrease in gonadotrophins such that around 15% of women 20-30 years past the menopause had concentrations as observed in reproductive life. Oestradiol concentrations were low throughout, although six patients more than 20 years past their menopause showed oestradiol concentrations in the lower end of the normal reproductive range (Table 1) . It is worth noting that FSH and LH concentrations may be suppressed transiently in postmenopausal women with critical illness, e.g, stroke, subarachnoid haemorrhage and head trauma.P In more than 50% of postmenopausal women admitted to intensive care units (medical, cardiac, surgical and neurological), premenopausal concentrations of LH and FSH have been found in association with hypothyroxinaemia.P
Oestrone
Serum oestrone concentrations decline by 50-800/0 at the menopause but, owing to decreasing production of oestradiol, oestrone becomes quantitatively the most abundant oestrogen in postmenopausal serum ( Table 2) . Circulating oestrone arises from the peripheral aromatization in adipose tissue of androstenedione from the adrenal gland.l" This peripheral aromatization increases gradually during the perirnenopause and is also positively correlated with obesity, i.e. the amount of adipose tissue.J' The ovarian contribution to the oestrogen pool postmenopausally is insignificant and direct production of oestrone by the adrenal gland is negligible. The small quantities of oestradiol circulating postmenopausally arise predominantly from Ann Clin Biochem 1994: 31 extra glandular metabolism of oestrcne.P The concentration of sex hormone binding globulin (SHBG) does not change significantly at the menopause so that measurement of total steroid hormones which are significantly bound to SHBG (testosterone, oestradiol) will reflect the free circulating concentration."
Androgens
In premenopausal women, around 25% of the circulating testosterone is secreted by the adrenal gland and 25% by the ovary. The remaining 50% is derived from the conversion of androstenedione to testosterone in peripheral tissues. The adrenal and ovary also contribute similar amounts to the circulating pool of androstenedione before the menopause. In the postmenopausal woman, androstenedione concentrations decrease by more than 50%31,3S but the ovary still contributes a small but significant amount (20%) to this reduced pool. 38 Interconversion to testosterone will also decrease at the rnenopause.P By contrast the ovarian stroma responds to the high circulating concentrations of LH and FSH by doubling the secretion of testosterone compared to the premenopausal ovary. 38 The net effect is a slight decrease in peripheral testosterone concentrations in serum (Table 2 ) and this can be detected early in the menopausal transition."
Decreases in dehydroepiandrosterone and its sulphate, primarily adrenal androgens, may be age rather than menopause-related."
lnhibin The gonadal glycoprotein hormone, inhibin, preferentially inhibits the production of FSH and completes a closed-loop feedback system between the ovary and pituitary gland. Follicular phase inhibin concentrations in serum decline significantly after 40 years of age and there is a negative correlation with FSH concentrations. 22 The fall in inhibin may reflect altered granulosa cell function in the production of this hormone or a fall in follicular number with age. Serum inhibin may provide a sensitive and early index of declining ovarian function but it is unclear whether such measurements have significant advantage over serum FSH.
THE CLINICAL VALUE OF HORMONE TESTS OF MENOPAUSAL STATUS
Clinical indications for biochemical confirmation of menopause
The perimenopause can frequently be determined in women over the age of 45 years on clinical grounds alone due to the close temporal association of symptoms with menstrual disturbance. There are some situations, however, where biochemical confirmation that a woman is peri-or postmenopausal would be helpful.
Identification of premature menopause
Premature menopause is defined by convention as ovarian failure occurring before 40 years of age.I? However, the normal age range (950/0 confidence interval) for natural menopause is 45-55 years-so that menopause before age 45 years could be considered as premature. The longterm risks of osteoporosis and atherosclerosis increase after early surgical menopause'J-" and osteoporosis risk increases with time since menopause.r" It is, therefore, widely accepted that women with premature menopause should be targeted for HRT. The possibility of premature menopause should be considered in women under the age of 45 years presenting with secondary
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Although the term amenorrhoea is generally applied when there have been no periods for at least 6 months, patients may often present earlier than this. Premature menopause may occur spontaneously or be associated with chromosomal or autoimmune disorders." Increasingly the cause may be iatrogenic due to radio/chemotherapy regimes for malignant disease. In addition, it has been suggested that women who have undergone hysterectomy with conservation of the ovaries are at risk of earlier menopause, by an average 4 years, due to disruption of the ovarian blood supply,42 although another study found no hormonal data to support this. 43 Since some women with premature menopause may not exhibit typical oestrogen deficiency symptoms, clinical identification may be difficult and hormone measurements have an accepted role.
The demonstration of persistent postmenopausal FSH concentrations in serum together with amenorrhoea supports the diagnosis of primary ovarian failure. The lower reference limit for serum FSH in postmenopausal women is reported as 30-40 U/L,41,44 but this will be method-dependent. Since concentrations may fluctuate to premenopausal levels during the menopausal transition, it is recommended'! that at least two sets of gonadotrophin estimations be made 4-8 weeks apart to add weight to the diagnosis. The degree of confidence with which FSH results can be interpreted increases with the duration of amenorrhoea such that after I year of amenorrhoea the diagnosis of menopause is almost certain. Significant amounts of oestradiol may be secreted in the early postmenopause, and therefore oestradiol measurements are unlikely to improve upon the predictive value of FSH in this situation.
It is important to recognize that ovarian failure (both spontaneous and iatrogenic) may be transient as isolated cases have been reported of the resumption of cyclical menses and/or pregnancy after a diagnosis of hypergonadotrophic amenorrhoea.v-v If fertility is sought, Rebar 41 recommended weekly measurements of serum LH, FSH and oestradiol for I month in order to identify women with some evidence of follicular maturation. The presence of viable oocytes might be indicated by finding oestradiol > 180 pmol/L or LH: FSH > 1 (by RIA) in anyone sample.
However, many gynaecologists would perform perimenopause. In the latter approach, two FSH concentrations> 30 U/L taken 4-8 weeks apart together with amenorrhoea are taken to indicate significant loss of ovarian function. A nonhormonal contraceptive is then recommended for a further 1 year in women over the age of 50 years and for 2 more years in younger women. so There are no data available on the efficacy of this second approach. It may prove effective, however, due to a combination of factors producing diminished fertility including age, raised FSH levels and a degree of pituitary suppression by the oestrogen component of the HRT. The disadvantage is the temporary return of oestrogen-responsive symptoms.
Selection of women for HRT
This section relates to women under the age of 45 years seeking HRT and to women presenting with symptoms which may be attributable to the menopause but in whom the diagnosis is not certain clinically. A survey of the age distribution of menopause-related requests received in our laboratory ( Fig. 4) indicates that the distribution lies to the left of that described by Treloar/ for perimenopausal women with a bias toward women at the start of this transition, i.e. median age 45 years. This reflects the fact that clinicians may have difficulty distinguishing oestrogen deficiency symptoms from those due to premenstrual syndrome and psychiatric or sociodomestic problems in women aged [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] The oestrogen-containing oral contraceptive prevents ovulation by suppression of gonadotrophin secretion and will mask the symptoms of ovarian failure. In premenopausal women, LH and FSH are suppressed by at least 50070 and may be undetectable by current assays. 47, 48 In postmenopausal women, an 80DJo suppression of FSH has been reported for women given 50 p.g ethinyl oestradiol. 49 The progestogen component of the combined pill will ensure regular monthly withdrawal bleeds irrespective of menopausal status. The question of premature menopause therefore, arises in women who become amenorrhoeic on stopping the combined pill. FSH measurements are of value as described above provided sufficient time has elapsed since stopping the pill to allow recovery of the gonadotrophs. There are data 47,48 to show that gonadotrophin levels return to normal after 1 week. However the patient is unlikely to present until 6-8 weeks after stopping the pill when FSH concentrations should be unaffected. so The progestogen-only pill (POP) has a much less suppressive effect on gonadotrophins and will not relieve vasomotor symptoms or amenorrhoea due to the menopause. Raised FSH levels on two separate occasions in a woman taking the POP usually indicates ovarian failure. so
Assessment of the need for contraception in women of menopausal age
It is known that 9DJo of women over the age of 45 years with 6 months of amenorrhoea will resume menstruations! and that ovulation can occur right up to the menopause in spite of 'postmenopausal' hormone profiles. Hormone measurements cannot, therefore, provide a secure basis for giving contraceptive advice. Current recommendations are that non-hormonal methods of contraception should be continued until 1 year of amenorrhoea has passed in women over the age of 50 years and 2 years in younger women. so As with the combined oral contraceptive, the date of the menopause will be masked in women who commence HRT before the menopause. As standard HRT is not contraceptive, the use of a non-hormonal method is required. Whitehead and Godfree suggest two approaches to giving advice. The clinical approach is to recommend contraception until the age of 55 years; this may be less acceptable and unnecessary in a proportion of women. The alternative approach is to use FSH measurements whilst off HRT as evidence of the years. 51 The risks and benefits related to longterm use of HRT are also complex but need to be addressed in view of the fact that a significant number of women may require HRT for relief of vasomotor symptoms for more than 5 years. 52 The rise in demand for a biochemical test which might help select patients for HRT is understandable.
There are few studies in the literature assessing the value of hormone measurements in predicting the response to HRT. Chakravati et al. 21 selected 82 patients attending a menopause clinic aged over 45 years who had near-regular cycles.Women were excluded if they had not menstruated in the last 3 months. In view of this and their age, it would be more accurate to consider these women as just at the start of the menopausal transition. A detailed record of symptoms was made before HRT was commenced and following 3 and 6 months of treatment. The group was sub-divided according to the presence or absence of vasomotor symptoms at the first attendance. Headaches and insomnia were common symptoms among women experiencing vasomotor disturbance, whereas depression was more prevalent in those without hot flushes. A high percentage of patients in the first group reported an improvement in their vasomotor and other symptoms whereas few patients without hot flushes noted any improvement in their 'menopausal symptoms' whilst on HRT. The striking finding was that a cut off of FSH = 15 U/L divided the two subgroups, there being greater overlap of LH and oestradiol levels. The FSH method employed was a double antibody RIA. The authors concluded that the presence of vasomotor disturbance and FSH > 15 U/L were the best criteria to select patients for HRT.
As discussed earlier, serum FSH is the most sensitive indicator of the menopausal transition, when concentrations> 15 U/L by conventional RIAI8,2O,31 and immunoradiometric assay (Boots Celltech IRMA, no longer in productionj" are often found in the follicular phase of the cycle. LH is of value for exclusion of sampling during the LH surge in women with irregular cycles and prior to the menopausal transition when a shortening of the length of the follicular phase has been reported. 18 Lee et al. 2O found that mean mid-cycle FSH concentrations by RIA increased from 8 U/L to 18 U/L in women aged 46-50 years compared to women of 25-35 years, whereas peak LH concentrations did not differ with age but were much higher than FSH (around 40 U/L by RIA). In our experience, mid-cycle
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FSH levelsin younger women measured by IRMA (lmmunodiagnostics Ltd, Tyne and Wear, UK) rarely exceed 25 U/L but a result > 15 U/L could be incorrectly interpreted without an accompanying LH level. For this reason and for ease of lab management, we measure both FSH and LH for menopause-related requests. A raised LH: FSH ratio due to polycystic ovarian syndrome and causing menstrual disturbance may also be detected by this approach although the sensitivity of this ratio may be reduced when immunometric methods are used compared to RIA. 53 The value of oestradiol measurements is questionable here due to the overlap of normal follicular and postmenopausal ranges. Results typical of those women described in Fig. 4 are illustrated in Fig. 5(a) and (b), subdividing the patients according to their FSH level. Starting HRT before the menopause can cause difficulties: (a) regarding contraceptive advice (see above); and (b) in synchronizing exogenous with endogenous hormone fluctuations. Irregular vaginal bleeding and symptoms of oestrogen excess can result when endogenous ovarian steroid production is high. Where symptoms are mild Whitehead recommends that HRT be withheld. 50 Where the diagnosis is uncertain, FSH measurement is of value, e.g. when symptoms are non-specific, menstruation is fairly regular and vasomotor problems are absent." Since prolonged use of HRT for more than 10 years may be associated with increased risk of breast cancer, a further justification for FSH measurement can be made for women <45 years seeking HRT.
Just as menstruation can resume sporadically thoughout the transition, FSH concentrations may be temporarily suppressed to pre-menopausal levels leading to 'false negative' results. There are no data to assess the predictive value of serum FSH as a test of the menopausal transition. Whitehead and colleagues" ,50 have found hormone investigations frequently unhelpful in the early climacteric. The evidence from Lenton et al. would suggest that attention to sampling during the follicular phase would improve the sensitivity of serum FSH measurements. 18,20 The frequency of false negative results also decreases close to the menopause." In most women therefore, a consistent hormonal profile occurs only when clinical indicators make the diagnosis relatively straightforward, i.e, age > 45 years with menopausal symptoms closely associated with oligomenorrhoea or amenorrhoea. Since hormone measurements are also of little guide to the eventual severity or duration of symptoms, they LH FSH LH FSH LH FSH (a) have little role to play in identifying those women >45 years who should be treated with HRT. 
$~~M
anagement of women with menstrual problems Women with heavy periods may be willing to tolerate this problem if there is evidence that the menopause is approaching. The demonstration of persistent, clear elevation in serum FSH might support this and help in the choice between medical and surgical treatment. Clinical studies are necessary to validate this approach.
Guidelines for biochemical investigation of women seeking help for menopausal symptoms
The guidelines given in Table 3 are intended to assist in the effective use of hormone tests in women seeking help for menopausal symptoms and/or advice on the use of HRT. Circumstances where they may be of value have been detailed above. Hormone results alone cannot be used as a basis for contraceptive advice. The general approach advocated is: (Table 3) . With regular cycles measure in thejollicular phase, days 1-7, for meaningful interpretation (FSH is raised in the mid-cycle surge; progesterone and inhibin in the luteal phase suppress FSH). In women over the age of 45 years, the menopause as the cause of symptoms is highly probable and therefore hormone measurements are not indicated unless the patient has regular cycles and equivocal symptoms. In younger women, with regular cycles a raised FSH level may be associated with symptoms more likely to respond to HRT. In younger women with irregular cycles, FSH is the most sensitive test of the perimenopause. However, a normal FSH result does not exclude the diagnosis. With secondary amenorrhoea, pregnancy should be excluded as the cause and then gonadotrophin measurements made to diagnose premature menopause. Oestradiol measurements may also be helpful in younger women as an indicator of residual ovarian function and possible fertility. Women who have had a hysterectomy prior to age 45 years have lost an important biological marker of the menopausal transition and may be at greater risk ofpremature ovarianfailure. They should have serum FSH checked periodically as an objective measure of ovarian failure.
Future trends: urine 'stick' tests ofthe menopause
A 'stick' test for the measurement of FSH in a 24-h urine collection was described in 1987 and shown to correlate well with conventional urine RIA measurements. 54 Such a test has not been developed commercially and there is no wide experience in the UK of the analytical reliability of urine FSH measurements. Although it was claimed that two to three positive stick tests in I week could reliably distinguish the menopause from other cause of amenorrhoea, this hormonal approach will have the same limitations as highlighted in this review for serum measurements compounded with errors in performing the test outside the laboratory and with possible false positive results arising due to sampling at midcycle. Nevertheless, just as urine HCG and LH 'stick' tests have been utilized by the general public to identify pregnancy and the fertile time of the cycle, such a self-diagnostic test for 'the menopause' might readily find a market place in the future.
HORMONE REPLACEMENT THERAPY
Indications for HRT: possible long-term risks and benefits Originally, oestrogens alone were prescribed for the relief of menopausal symptoms (unopposed therapy). Long-term monitoring of the benefits, side effects and adverse effects of unopposed therapy has led to changes in the formulations of HRT available, including the addition of progestogens (combined therapy), and an extension of the indications for prescribing treatment.
The current licensed indications for prescribing HRT are summarized in Table 4 . ss The value of HRT prescription as a public health strategy in the prevention of osteoporosis and subsequent fractures is currently under investigatiorr" and may not be as useful as initially proposed (see Law et al. for discussion'"). The role of HRT in reducing morbidity and mortality rates from IHD and cerebrovascular disease (CVD) is also uncertain at present, as no randomized prospective studies have been performed. The data from prospective cohort studies indicate that unopposed oestrogen therapy is associated with a greatly reduced risk of IHD, with an average 5011/0 reduction in mortality.S8-60 The data on CVD risk are less certain.s? It is impossible to exclude all bias from treatment groups in such studies and randomized trials are urgently needed. 61,62 Furthermore, the formulations of HRT have already changed from those in use in these studies, because of identification of a two to four-fold increased risk of endometrial carcinoma in women with an intact uterus prescribed oestrogens alone. 63 ,64 The addition of an adequate dose of a progestogen converts the endometrium from a proliferative to a secretory pattern'" and allows regular withdrawal bleeds with prevention of the increased risk of endometrial carcinoma. 66, 67 Many studies have also assessed the risk of breast carcinoma in women on HRT. This risk, if any, is small. Meta-analysis suggests that therapy for more than 10 years may be associated with a 1· 5-to two-fold increased risk of breast cancer. 60, 68 As yet, there is little information on the long-term effects of combined oestrogen and progesterone therapy." Cervical carcinoma rates have not been shown to be affected by HRT,63,69 but further work is needed to explore the relationship between ovarian cancer and HRT.69 A comprehensive review of these issues has been published recently.70
Formulations and pharmacological effects of HRT Oestrogens
The structural formulae of some natural and synthetic oestrogens are shown in Fig. 6 . Oestrogens may be delivered orally, transdermally ('patches'), or from subcutaneous implants, and each formulation of unopposed oestrogen has different dosages of oestrogen available." All routes of delivery are effective in relieving menopausal symptoms." The oestrogenic compounds used in combination HRT and principal circulating products are listed in Table 5 . Data on bone protection are not complete for transdermal preparations." Oral oestrogens lead to an increased oestrone: oestradiol ratio because of first pass hepatic metabolism, although this may be of little significance. Oestradiol implants and transdermal preparations avoid first pass hepatic metabolism, have less effect on hepatic protein metabolism than oral preparations and produce a more natural oestrone: oestradiol ratio. 12, 73 Implants have an unpredictable halflife and can result in hormone accumulation with unphysiological high concentrations of oestradiol for prolonged periods of time." Oestrogen creams are also available for local vaginal application. 
Progestogens
Natural progestogens are rapidly inactivated when taken orally because of metabolism in the gut and liver." Synthetic derivatives have therefore been used which vary in their affinity for different steroid receptors and side effect profile. Those derived from testosterone (norethisterone and norgestrel) have mild androgenic side effects including a reduction in HDL-cholesterol and a natural oestrogens used in HRT 12 and the anticipated adverse effects of oestrogen therapy on blood pressure, thrombotic episodes and IHD in menopausal women have not been borne out. In fact, prospective cohort studies demonstrate a reduced risk of arterial thrombotic diseases in oestrogen users. 58, 59 This reduced risk may be a consequence of bias in patient selection for treatment,"! or may be secondary to the favourable effect which oestrogens have on the serum lipid profile. Both synthetic and natural oestrogens cause an increase in HDL-cholesterol, a reduction in the LDL fraction and an increase in triglycerides.F although this effect is less pronounced with transdermal preparations76 and in long-term studies. 10 It has also been proposed that oestrogens have direct effects on vessel tone which cause vasodilatation, possibly through effects on the balance between prostacycline and thrornboxane.P These should only be used short term as significant systemic absorption can occur.
The current data sheets issued by pharmaceutical companies in which the indications, contraindications and cautions for therapy are stated have largely derived from data on the oral contraceptive pill (OCP). The adverse effects of the OCP on blood pressure and coagulation are thought to be due to the powerful effects of ethinyl oestradiol on liver protein synthesis. There is increased production of plasma renin substrate and of clotting factors.'? This effect is not seen with the FIGURE 6. Structuralformulae for natural human and equine oestrogens and synthetic oestrogens used in hormone replacement therapy (HRT) (adapted from Khul, 1990 with permission"). 67 ,73 More recent derivatives are without androgenic side effects (desogestrel, gestodene, norgestimate) and do not affect the lipoprotein profile.P From data on oral contraceptives, there is little evidence that increasing doses of progestogens affect coagulation status but there may be some increase in blood pressure.P Progestogens alone may provide some relief from menopausal symptoms when prescribed to women in whom oestrogens are contraindicated, but they have not been shown to protect against osteoporosis, except in high dosage.1 2 ,71 Choice oj therapy Transdermal preparations were developed to provide a reversible form of therapy which avoided the adverse effects on hepatic protein synthesis of oral first pass metabolism, and the need for depot insertion. Now that there is less concern over the risk of thrombosis and more interest in the favourable lipid profile produced by oral oestrogens, there is less support for the transdermal route. Women who have had a hysterectomy should be prescribed unopposed oestrogen therapy as they have no need for endometrial protection with a progestogen.55 Women with a uterus require combined therapy with a progestogen. This will lead to more predictable cycle control than unopposed treatment as well as reducing the risk of endometrial carcinoma.s? Unfortunately, a large proportion of the nuisance side effects which women experience are due to the progestogen component, e.g. bloating, breast tenderness, premenstrual symptoms which may limit compliance. Some clinicians will prescribe unopposed oestrogen to women with an intact uterus who cannot tolerate progestogens, provided that they agree to regular endometrial sampling. 12, 66 The choice of treatment depends on the potential benefits, side effects and risks of different formulations for an individual woman. Hormone tests have no role in determining the initial choice oj treatment. The main features of the different classes of drug are summarized in Table 6 .
New developments
The main complaint from women prescribed combined HRT in its current formulations is the resultant withdrawal bleeds. Attempts have therefore been made to avoid this.
Continuous combined therapy: Instead of cyclical progesterone therapy, oestrogen and a progestogen are taken together continually to prevent endometrial proliferation. In approximately 60070 of patients, endometrial atrophy and amenorrhoea occur. Others have unacceptable irregular bleeding." This type of preparation may therefore prove to have improved patient compliance in a proportion of patients.
Tibolone: This is a steroid derivative which combines oestrogenic, progestational and weak androgenic actions. It is effective in relieving menopausal symptoms and, if prescribed to postmenopausal women, rarely causes endometrial stimulation and bleeding. There are limited data on its long-term effects. 77 Use of the OCP until the menopause: In the UK the upper age limit for prescription of the combined OCP is 45 years. In America, an expert committee have advised the Food and Drugs Administration (FDA) to remove this upper age limit for healthy, non smoking women." In the future, therefore, if the UK follows suit, a proportion of women in low risk categories may Conjugated equine oestrogens are the most commonly prescribed form of oestrogen.P This results in a complex mixture of oestrogenic substances in blood of different biological potency49,73 which will be detected to variable extents in immunoassays for oestradiol which use antisera of different specificities.v-" For example, a good correlation exists using the INCSTAR Clinical Assays (Wokingham, UK) oestradiol RIA for results obtained before and after etherextraction of the sample (Fig. 7a ). This is not the case for the more widely used Diagnostic Products (DPC: Abingdon, UK) double antibody method (Fig. 7b) where high results are obtained if the kit is used for women taking conjugated equine oestrogens,81-84 Trisequens" and some other oral preparations.P'r" The lack of specificity of the DPC assay may be due to the use of the threelinked immunogen for the production of the antiserum, rather than a six-linked immunogen. DPC now recommends that the kit should not be used to measure oestradiol in women prescribed HRT unless an extraction step is included. Conversely, other direct (non-extraction) kits may underestimate the serum oestradiol concentration.t' possibly due to inadequate displacement of oestradiol from the raised SHBG levels which arise due to oral oestrogen administration.P In view of the methodological uncertainties and the fact that oestradiol is only On treatment: A 3 month follow up is recommended to assess clinical efficacy and side effects, followed by 6 monthly review. Where there is concern over the lipid profile, this can be reviewed at each appointment with appropriate advice."
The main indication for measuring oestradiol is to check the concentration in women with oestradiol implants prior to the next depot insertion to ensure that there is no accumulation of drug.?? Subcutaneous (and transdermal) delivery systems avoid first pass hepatic metabolism and do not affect concentrations of SHBG or oestrogen conjugates markedly. 79, 83 Oestradiol assays should therefore give valid results in these circumstances. A falling concentration, rather than a low level may induce hot flushes and premature replacement may lead to very high concentrations of oestradiol." There is no consensus on the oestradiol concentration in serum at which insertion of a new implant should be witheld. Some authors advise that oestradiol concentrations should fall to below 200 pmolll whereas others argue that concentrations in excess of 1()()() pmol/l may be necessary for alleviation of depressive symptorns.Iv" Gonadotrophin concentrations may be suppressed in women with implants,88,89 but this may not be an appropriate therapeutic end point since physiological gonadotrophin suppression is a result of both steroid and inhibin action. Since concentrations of SHBG do not increase markedly, it is likely that the free oestradiol concentration is maintained at very high levels in a proportion of patients. The long-term safety of such supraphysiological concentrations is uncertain and is therefore probably best avoided where possible."
There may be some value in measuring oestradiol concentrations in women with transdermal patches where symptoms are not relieved, and there are concerns about adequate absorption through the skin. However, the low levels achieved are at the limits of sensitivity of many current immunoassays.72,79,83 Oestradiol patches are replaced every 3 days, the timing of the peak level achieved can vary and the average level will also depend on the drug dosage in the patch administered.P'"? The indications for measuring reproductive hormones during HRT therapy are therefore limited and are summarized in Table 7 .
Future trends: optimization of HRT to prevent osteoporosis There is evidence that bone resorption starts to increase at the perimenopause.P'<"
In one study, perimenopausal women identified by having a follicular phase FSH > 12 U/L, had significantly lower bone density in the lumbar spine and femoral neck than women in the [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] year age group who had FSH < 12 U/L,92 It has also been suggested that HRT might be optimized for the individual by titrating the dose to reduce FSH concentrations to 'at least that level considered to be diagnostic of the menopause' . 93 Although there is some evidence that suppression of FSH to premenopausal levels with oestradiol implant therapy results in greater bone density,88,89 it is not clear whether the fracture incidence is reduced compared to standard doses of HRT. The significance of supraphysiological oestradiol levels also needs to be clarified before hormone measurements can be assigned a wider role in the monitoring of HRT.
CONCLUSION
In the normal menstrual cycle there are large but regular fluctuations in circulating reproductive hormone levels. During the menopausal transition, the frequency of ovulatory cycles declines and further marked variation is superimposed on this dynamic system. Measurements of hormones in serum provide a 'snapshot' of the pituitaryovarian axis which must be viewed as potentially misleading for the highly unpredictable time of the perimenopause. In most women, the perimenopause can be diagnosed clinically and the routine biochemical investigation of women over the age of 45 years with oligo/amenorrhoea should be discouraged as the results will add little to the diagnostic certainty of the perimenopause in this age group. In younger women with menstrual disturbance other diagnoses are more likely and biochemical investigation is therefore of value in confirming the clinical diagnosis. When blood samples are taken, FSH and LH results are most readily interpreted if the woman is amenorrhoeic or if the sample has been taken at the time of menses (day 1-7 of the cycle) when FSH secretion is most sensitive to declining ovarian function. Normal menstruating concentrations of FSH can occur during the menopausal transition although the frequency of this is unknown for samples taken during the follicular phase of the cycle. The FSH result should therefore be interpreted cautiously in relation to the patient's age, her menstrual history and symptoms. Serum oestradiol measurements may be of value in younger women with premature ovarian failure in demonstrating residual follicular activity and therefore some chance of the return of fertility. There is little role, at present, for the measurement of reproductive hormones in women prescribed HRT with the exception of oestradiol measurements in serum to assess the function of oestrogen implants in patients with recurrent menopausal symptoms.
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